N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: A novel class of potent orally active human NK1 antagonists

被引：64

作者：

Ladduwahetty, T ^{[1
]}

Baker, R ^{[1
]}

Cascieri, MA ^{[1
]}

Chambers, MS ^{[1
]}

Haworth, K ^{[1
]}

Keown, LE ^{[1
]}

MacIntyre, DE ^{[1
]}

Metzger, JM ^{[1
]}

Owen, S ^{[1
]}

Rycroft, W ^{[1
]}

Sadowski, S ^{[1
]}

Seward, EM ^{[1
]}

Shepheard, SL ^{[1
]}

Swain, CJ ^{[1
]}

Tattersall, FD ^{[1
]}

Watt, AP ^{[1
]}

Williamson, DW ^{[1
]}

Hargreaves, RJ ^{[1
]}

机构：

[1] MERCK & CO INC,MERCK SHARP & DOHME RES LABS,RAHWAY,NJ 07065

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 1996年 / 39卷 / 15期

关键词：

D O I：

10.1021/jm9506534

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The preparation of a series of N-heteroarylpiperidine ether-based human NK1 antagonists is described. Two of the compounds (3-[{(2S,3S)-3-(((3,5-bis(trifluoromethyl)phenyl)methyl)oxy)- 2-phenylpiperidino)methyl]-1,2,4-triazol (11) and 5-[((2S,3S)-3-(((3,5-bis(trifluoromethyl phenyl)methyl)oxy)-2-phenylpiperidino}methyl]-3-oxo-1,2,4-triazole (12)), in particular, are orally bioavailable and exhibited significant improvements in potency, both in vitro and in vivo, over the lead (carboxamidomethyl)piperidine ether 1. Rat Liver microsome studies on a selected number of compounds from this series show the triazolone heterocycle to be considerably more stable than the others. Furthermore, both 11 and 12 have been profiled in a number of assays that may be predictive of the clinical utility of substance P antagonists.

引用

页码：2907 / 2914

页数：8

共 33 条

[1] BAKER R, 1993, Patent No. 4040
[2] CARDIOVASCULAR EFFECTS OF CP-96,345, A NONPEPTIDE BLOCKER OF TACHYKININ NK1 RECEPTORS
CONSTANTINE, JW
LEBEL, WS
WOODY, HA
BENOIT, PA
WOLFGANG, EA
KNIGHT, DR
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 252 (03) : 275 - 282
[3] PHARMACOLOGICAL PROPERTIES OF A POTENT AND SELECTIVE NONPEPTIDE SUBSTANCE-P ANTAGONIST
GARRET, C
CARRUETTE, A
FARDIN, V
MOUSSAOUI, S
PEYRONEL, JF
BLANCHARD, JC
LADURON, PM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) : 10208 - 10212
[4] DESIGN OF A NOVEL DIPEPTIDE SUBSTANCE-P ANTAGONIST FK888
HAGIWARA, D
MIYAKE, H
IGARI, N
MURANO, K
MORIMOTO, H
MURAI, M
FUJII, T
MATSUO, M
[J]. REGULATORY PEPTIDES, 1993, 46 (1-2) : 332 - 334
[5] STUDIES ON NEUROKININ ANTAGONISTS .1. THE DESIGN OF NOVEL TRIPEPTIDES POSSESSING THE GLUTAMINYL-DEUTERIUM-TRYPTOPHYLPHENYLALANINE SEQUENCE AS SUBSTANCE-P ANTAGONISTS
HAGIWARA, D
MIYAKE, H
MORIMOTO, H
MURAI, M
FUJII, T
MATSUO, M
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (11) : 2015 - 2025
[6] HARGREAVES RJ, 1994, CAN J PHYSL PHARM S2, V72, P45
[7] PIPERIDINE-ETHER BASED HNK(1) ANTAGONISTS .1. DETERMINATION OF THE RELATIVE AND ABSOLUTE STEREOCHEMICAL REQUIREMENTS
HARRISON, T
WILLIAMS, BJ
SWAIN, CJ
BALL, RG
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (21) : 2545 - 2550
[8] PIPERIDINE-ETHER BASED HNK(1) ANTAGONISTS .2. INVESTIGATION OF THE EFFECT OF N-SUBSTITUTION
HARRISON, T
OWENS, AP
WILLIAMS, BJ
SWAIN, CJ
BAKER, R
HUTSON, PH
SADOWSKI, S
CASCIERI, MA
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (03) : 209 - 212
[9] REACTIONS OF LITHIOOXAZOLE
HODGES, JC
PATT, WC
CONNOLLY, CJ
[J]. JOURNAL OF ORGANIC CHEMISTRY, 1991, 56 (01) : 449 - 452
[10] KISFALUDY L, 1987, SYNTHESIS-STUTTGART, P510

← 1 2 3 4 →